A Phase II Safety, Efficacy, and Feasibility Study of Neoadjuvant ZD1839 (IRESSA) [gefitinib] in Resectable Esophageal Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2013 Additional lead trial investigator added as reported by ClinicalTrials.gov record.
- 25 Jan 2008 Status changed from recruiting to discontinued.